Neonatal Medication Guideline

Clinical Guideline

Dopamine

Policy developed by: SA Maternal, Neonatal & Gynaecology Community of Practice
Approved SA Health Safety & Quality Strategic Governance Committee on: 6 October 2010
Next review due: 6 October 2010

Summary
The purpose of this guideline is to guide nursing, midwifery, medical and pharmacy staff in the dosing and administration of dopamine

Keywords
Dopamine, neonatal medication guideline, inotrope, circulatory support, severe sepsis, septic shock, hypotension, tachycardia, tachyarrhythmia, phaeochromocytoma, TSH

Policy history
Is this a new policy? N
Does this policy amend or update an existing policy? Y v1.0
Does this policy replace an existing policy? N
If so, which policies?

Applies to
All SA Health Portfolio
All Department for Health and Ageing Divisions
All Health Networks
CALHN, SALHN, NALHN, CHSALHN, WCHN, SAAS

Staff impact
All Clinical, Medical, Midwifery, Nursing, Students, Allied Health, Emergency, Mental Health, Pathology, Pharmacy

PDS reference CG025

Version control and change history

<table>
<thead>
<tr>
<th>Version</th>
<th>Date from</th>
<th>Date to</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>November 2012</td>
<td>October 2017</td>
<td>Original version</td>
</tr>
<tr>
<td>2.0</td>
<td>6 October 2017</td>
<td>Current</td>
<td>Review</td>
</tr>
</tbody>
</table>

© Department for Health and Ageing, Government of South Australia. All rights reserved.
South Australian Neonatal Medication Guidelines

DOPamine
40mg/mL injection

© Department of Health, Government of South Australia. All rights reserved

Note

This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient’s medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

- The use of interpreter services where necessary,
- Advising consumers of their choice and ensuring informed consent is obtained,
- Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
- Documenting all care in accordance with mandatory and local requirements

This is a High Risk Medication ⚠️
An overdose can be rapidly fatal.

Dose and Indications

Circulatory Support

Hypotension

Severe sepsis and septic shock

Intravenous infusion

3 to 20 micrograms/kg/minute; commence at low dose and titrated dose every 5-10 minutes if required according to clinical response.
Preparation and Administration

**Intravenous Infusion**

Administer preferably via a central line but may be used peripherally in an emergency when central access is not available.

Select the strength required based on the weight of the infant in the context of any fluid restrictions. DOPamine Concentration Selection Tables can be found on the following pages of this guideline to assist prescribers to gauge which strength is best for the patient.

Dilute the appropriate volume of DOPamine injection using compatible fluid; and administer by continuous infusion. Diluted preparation is stable for 24 hours at room temperature. Discard any remaining solution.

The three standard concentrations to select from are:

- DOPamine 0.8mg/mL (800micrograms/mL)
- DOPamine 1.6mg/mL (1600micrograms/mL)
- DOPamine 3.2mg/mL (3200micrograms/mL)

### Formulae

**To calculate infusion rate (mL/hr):**

\[
\text{Rate (mL/hr)} = 60 \times \text{dose (micrograms/kg/min)} \times \text{weight (kg)} \div \text{Strength (micrograms/mL)}
\]

**To calculate the dose (micrograms/kg/min):**

\[
\text{Dose (micrograms/kg/min)} = \frac{\text{Rate(mL/hr)} \times \text{Strength (micrograms/mL)}}{60 \times \text{weight (kg)}}
\]
Dilution for DOPamine 800micrograms/mL

To make **25ml syringe:**
Dilute 0.5mL DOPamine (40mg/mL) with 24.5mL of compatible fluid (total of 25mL). The resulting solution contains 800micrograms/mL DOPamine.

To make **50ml syringe:**
Dilute 1mL DOPamine (40mg/mL) with 49mL of compatible fluid (total of 50mL). The resulting solution contains 800micrograms/mL DOPamine.

Table 1: Concentration selection table for DOPamine 800micrograms/ml
Recommended for neonates weighing <1kg

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Rate (mL/hr)</th>
<th>0.2</th>
<th>0.3</th>
<th>0.4</th>
<th>0.5</th>
<th>0.6</th>
<th>0.7</th>
<th>0.8</th>
<th>0.9</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.5</td>
<td>2</td>
<td>5</td>
<td>8</td>
<td>11</td>
<td>13</td>
<td>16</td>
<td>19</td>
<td>21</td>
<td>24</td>
<td>27</td>
</tr>
<tr>
<td>1</td>
<td>3</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>7</td>
<td>8</td>
<td>9</td>
<td>11</td>
<td>12</td>
<td>13</td>
</tr>
<tr>
<td>1.5</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td>8</td>
<td>9</td>
</tr>
<tr>
<td>2</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>2.5</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>4</td>
<td>4</td>
<td>5</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>4</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>3.5</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>
Dilution for DOPamine 1600micrograms/mL

**To make 25ml syringe:**
Dilute 1mL DOPamine (40mg/mL) with 24mL of compatible fluid (total of 25mL). The resulting solution contains 1600micrograms/mL DOPamine.

**To make 50ml syringe:**
Dilute 2mL DOPamine (40mg/mL) with 48mL of compatible fluid (total of 50mL). The resulting solution contains 1600micrograms/mL DOPamine.

Table 2: Concentration selection table for DOPamine 1600micrograms/mL
Generally used for neonates weighing 1kg to 3kg

<table>
<thead>
<tr>
<th>Rate (mL/hr)</th>
<th>0.2</th>
<th>0.3</th>
<th>0.4</th>
<th>0.5</th>
<th>0.6</th>
<th>0.7</th>
<th>0.8</th>
<th>0.9</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight (kg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>5</td>
<td>8</td>
<td>11</td>
<td>13</td>
<td>16</td>
<td>19</td>
<td>21</td>
<td>24</td>
<td>27</td>
</tr>
<tr>
<td>1.5</td>
<td>4</td>
<td>5</td>
<td>7</td>
<td>9</td>
<td>11</td>
<td>12</td>
<td>14</td>
<td>16</td>
<td>18</td>
</tr>
<tr>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>7</td>
<td>8</td>
<td>9</td>
<td>11</td>
<td>12</td>
<td>13</td>
</tr>
<tr>
<td>2.5</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td>9</td>
<td>10</td>
<td>11</td>
</tr>
<tr>
<td>3</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td>3.5</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td>4</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>5</td>
<td>6</td>
<td>7</td>
</tr>
</tbody>
</table>
Dilution for DOPamine 3200micrograms/mL

To make **25ml syringe:**
Dilute 2mL DOPamine (40mg/mL) with 23mL of compatible fluid (total of 25mL). The resulting solution contains 3200micrograms/mL DOPamine.

To make **50ml syringe:**
Dilute 4mL DOPamine (40mg/mL) with 46mL of compatible fluid (total of 50mL). The resulting solution contains 3200micrograms/mL DOPamine.

**Table 3: Concentration selection table for DOPamine 3200micrograms/mL**
Generally used for neonates weighing >3kg

<table>
<thead>
<tr>
<th>Rate (mL/hr)</th>
<th>0.2</th>
<th>0.3</th>
<th>0.4</th>
<th>0.5</th>
<th>0.6</th>
<th>0.7</th>
<th>0.8</th>
<th>0.9</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight (kg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>5</td>
<td>8</td>
<td>11</td>
<td>13</td>
<td>16</td>
<td>19</td>
<td>21</td>
<td>24</td>
<td>27</td>
</tr>
<tr>
<td>2.5</td>
<td>4</td>
<td>6</td>
<td>9</td>
<td>11</td>
<td>13</td>
<td>15</td>
<td>17</td>
<td>19</td>
<td>21</td>
</tr>
<tr>
<td>3</td>
<td>4</td>
<td>5</td>
<td>7</td>
<td>9</td>
<td>11</td>
<td>12</td>
<td>14</td>
<td>16</td>
<td>18</td>
</tr>
<tr>
<td>3.5</td>
<td>3</td>
<td>5</td>
<td>6</td>
<td>8</td>
<td>9</td>
<td>11</td>
<td>12</td>
<td>14</td>
<td>15</td>
</tr>
<tr>
<td>4</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>7</td>
<td>8</td>
<td>9</td>
<td>11</td>
<td>12</td>
<td>13</td>
</tr>
<tr>
<td>4.5</td>
<td>2</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td>8</td>
<td>9</td>
<td>11</td>
<td>12</td>
</tr>
<tr>
<td>5</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td>9</td>
<td>10</td>
<td>11</td>
</tr>
</tbody>
</table>
Compatible Fluids
Glucose 5%, glucose 10%, glucose/sodium chloride solutions, sodium chloride 0.9%

Adverse Effects

Common
Tachycardia, hypotension or hypertension

Infrequent
Arrhythmia, bradycardia, mydriasis, vasoconstriction, extravasation (may cause necrosis and sloughing of surrounding tissue)

Rare
Allergic reaction (due to sodium metabisulfite)

Monitoring
- Observe intravenous site for inflammation, extravasation and extreme vasoconstriction (tracking)
- Continuous heart rate
- Invasive blood pressure monitoring is recommended

Practice Points
- Correct hypovolaemia and acidosis prior to administration
- Doses >10 micrograms/kg/min can cause an increase in systemic resistance, fall in gastrointestinal blood flow and reduction in cardiac output especially in the first week of life
- DOPamine is incompatible with alkaline solutions such as sodium bicarbonate
- Phenytoin when given together with DOPamine may cause severe hypotension
- Do not bolus other drugs via DOPamine infusion
- Caution when changing IV line, avoid bolus or prolonged interruption of drug infusion
- Use cautiously in patients with heart disease, or persistent pulmonary hypertension
- Dopamine causes reversible suppression of serum TSH, T4 and prolactin levels in very low birth weight infants. Caution with long-term use.¹
- Contraindicated in ventricular fibrillation or other uncorrected tachyarrhythmias and phaeochromocytoma
References


Version control and change history

**PDS reference:** OCE use only

<table>
<thead>
<tr>
<th>Version</th>
<th>Date from</th>
<th>Date to</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>November 2012</td>
<td>October 2017</td>
<td>Original version</td>
</tr>
<tr>
<td>2.0</td>
<td>6 October 2017</td>
<td>Current</td>
<td>Review</td>
</tr>
</tbody>
</table>